The use of X-ray crystallography and molecular modeling to understand enzyme-inhibitor binding interactions can dramatically accelerate the process of optimizing early lead compounds, transforming them from leads with weak activities into highly potent and selective clinical candidates. Whenever possible, we incorporate these technologies into our drug discovery collaborations to maximize our effectiveness. Specific services include:

  • Protein production and purification
  • X-ray crystallography of small molecule inhibitors bound to protein targets
  • Molecular modeling for lead optimization
  • Biophysical analysis of protein-inhibitor interactions

Join Our Mailing List

Get the latest news and announcements from New England Discovery Partners